23 February 2021 - If approved, the vaccine may help reduce the risk of tick-borne encephalitis for people traveling to endemic areas, potentially including military personnel serving in these locations.

Pfizer today announced that the U.S. FDA accepted for priority review the company’s biologics license application for TicoVac, its tick-borne encephalitis vaccine for active immunization to prevent tick-borne encephalitis in individuals 1 year of age and older.

Read Pfizer press release